transkingdom RNA interference (tkRNAi) and the founding of Cequent

Document Sample
transkingdom RNA interference (tkRNAi) and the founding of Cequent Powered By Docstoc
					Johannes Fruehauf
Vice President, Research, Cequent Pharma

 Johannes studied Medicine in Germany (Frankfurt and Heidelberg) and France (Montpellier),
 and was trained as an Obstetrician/Gynecologist. He joined the Skip Ackerman Center for
 Molecular Therapeutics at Beth Israel Deaconess Medical Center /Harvard in Boston to do
 his postdoc and to develop RNAi therapeutics against cancer. This lead to the discovery of
transkingdom RNA interference (tkRNAi) and the founding of Cequent Pharmaceuticals. At
Cequent, Johannes is Vice President, Research and directs all research & development
efforts for Cequent’s therapeutic pipeline.